If You Had Bought Sage Therapeutics (NASDAQ:SAGE) Stock Three Years Ago, You Could Pocket A 410% Gain Today

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

For us, stock picking is in large part the hunt for the truly magnificent stocks. Not every pick can be a winner, but when you pick the right stock, you can win big. One such superstar is Sage Therapeutics, Inc. (NASDAQ:SAGE), which saw its share price soar 410% in three years.

Check out our latest analysis for Sage Therapeutics

Sage Therapeutics isn’t currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn’t make profits, we’d generally expect to see good revenue growth. That’s because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

The graphic below shows how revenue and earnings have changed as management guided the business forward. If you want to see cashflow, you can click on the chart.

NasdaqGM:SAGE Income Statement, May 30th 2019
NasdaqGM:SAGE Income Statement, May 30th 2019

Sage Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

We’re pleased to report that Sage Therapeutics rewarded shareholders with a total shareholder return of 14% over the last year. That falls short of the 72% it has made, for shareholders, each year, over three years. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

We will like Sage Therapeutics better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.